Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049419 | 0.80 | LRRK2 (0.44) | LRRK2DRD2PGRCYP11B1CYP11B2 | |
| SCHEMBL12070481 | 0.80 | CHRM4 (0.44) | CHRM4DRD2HTR7LMNAKDM4C | |
| SCHEMBL29187437 | 0.78 | LRRK2 (0.45) | LRRK2DRD2PPARDPPARADPP4 | |
| SCHEMBL29187438 | 0.78 | LRRK2 (0.45) | LRRK2DRD2PPARDPPARADPP4 | |
| SCHEMBL10823071 | 0.78 | ESR1 (0.49) | CHRM4DRD2HTR7KDM4C | |
| SCHEMBL23782826 | 0.78 | LRRK2 (0.48) | LRRK2DRD2PGRCYP11B1CYP11B2 | |
| SCHEMBL3823105 | 0.78 | ESR1 (0.49) | CHRM4DRD2HTR7KDM4C | |
| SCHEMBL3817898 | 0.78 | ESR1 (0.49) | CHRM4DRD2HTR7KDM4C | |
| SCHEMBL6991714 | 0.78 | PPARD (0.41) | LRRK2DRD2PGRLMNAHTR6 | |
| SCHEMBL4517438 | 0.77 | PGR (0.58) | LRRK2DRD2PGRCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | LRRK2 3238/4885CHRM4 794/4885DRD2 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.